Provided by Tiger Trade Technology Pte. Ltd.

Anti-Pandemic Concept

1,861.31
-6.2230-0.33%
Number of Gainers:6
Number of Losers:13
Number of Flat:- -
PE:- -
High:1,867.96
Open:1,864.69
Low:1,848.51
Close:1,867.50
Volume:68.28M
Turnover:4.71B
Market Cap:1.51T
Float Cap:1.48T

Loading ...

BioNTech Halts Phase 2 mRNA Monotherapy Trial in Resected Colorectal Cancer After DSMB Review

TIPRANKS
·
Aug 28

BioNTech Terminates Phase 2 Trial of Autogene Cevumeran in Colorectal Cancer

MT Newswires Live
·
Aug 28

Jefferies sees neutral to negative read-through to Alnylam from AstraZeneca data

TIPRANKS
·
Aug 28

Novavax’s partners approved for Nuvaxovid formulation for vaccination season

TIPRANKS
·
Aug 28

iBio Advances IBIO-600 into Phase 1 Multiple-Ascending-Dose Trial Stage After Completing Single-Ascending-Dose Dosing

Reuters
·
Aug 28

Novavax's Partnership Strategy Continues to Deliver with Xfg-Adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season

THOMSON REUTERS
·
Aug 28

Novavax, - Eligible for Royalties on Net Sales in U.S., EU, Japan for 2026-2027 Season

THOMSON REUTERS
·
Aug 28

Argus Research Upgrades Moderna to Buy From Hold, $180 Price Target

MT Newswires Live
·
Aug 28

Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes

Reuters
·
Aug 28

Moderna Price Target Announced at $180.00/Share by Argus Research

Dow Jones
·
Aug 28

U.S. Stocks on the MOVE-Cytokinetics, Moderna, Ulta Beauty

Reuters
·
Aug 28

Success After a Century of Failures: Inside Moderna and Merck's Cancer Vaccine Breakthrough

Reuters
·
Aug 28

Moderna Prices $2.6 Billion Convertible Notes due 2032

MT Newswires Live
·
Aug 28

Moderna Rises After Upsized $2.6 Bln Convertible Bond Sale

Reuters
·
Aug 28

iBio FY26 Net Loss Widens to $33.04 Million; Revenue Drops to $100,000

Reuters
·
Aug 28

Ibio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Aug 28

Press Release: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Dow Jones
·
Aug 28

Gilead Breaks Ground on Foster City Biologics Facility in $32 Billion US Investment Push

Reuters
·
Aug 28

Gilead Sciences Director Anthony Welters Disposes of USD 2.64 Million in Common Shares

Reuters
·
Aug 28

Gilead’s Bixlenvo approved by FDA for virologically suppressed adults with HIV

TIPRANKS
·
Aug 28